Nuevas terapias antirretrovirales en la infección por VIH
Luz Alicia González-Hernández(Universidad de Guadalajara), Jaime Andrade‐Villanueva(Hospital Civil de Guadalajara), Emmanuel Mercado–Núñez, Raúl Soria-Rodríguez, Edith Alejandra González-Vázquez, Mara Anaís Llamas-Covarrubias(Universidad de Guadalajara), José Alain García-Castro, Jorge Iván Arce-Rosas, Ariel Eduardo Campos-Loza(Universidad de Guadalajara)
Revista Médica MD
January 1, 2014
Cited by 1
Related Papers
Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial
|The Lancet Respiratory Medicine|2021|225
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
|The Lancet Infectious Diseases|2011|172
Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies
|Science Translational Medicine|2017|169
Oral Manifestations Associated with HIV/AIDS Patients
|Medicina|2022|97